{"id":"W3014500359","doi":"10.1097/coc.0000000000000691","title":"A Phase 1 Study of SLC-0111, a Novel Inhibitor of Carbonic Anhydrase IX, in Patients With Advanced Solid Tumors","year":2020,"lang":"en","type":"article","venue":"American Journal of Clinical Oncology","topic":"Enzyme function and inhibition","field":"Biochemistry, Genetics and Molecular Biology","cited_by":250,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; Welichem Biotech (Canada); SignalChem (Canada); Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Sanofi; GlaxoSmithKline; Servier; Pfizer; Eli Lilly and Company; Genentech; PTC Therapeutics; American Association for Cancer Research","keywords":"Medicine; Tolerability; Cmax; Discontinuation; Internal medicine; Pharmacokinetics; Nausea; Adverse effect; Dosing; Cohort; Vomiting; Gastroenterology; Response Evaluation Criteria in Solid Tumors; Pharmacology; Phases of clinical research; Toxicity","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004292363,0.0001217985,0.000875919,0.00007101232,0.00001157395,0.000001860817,0.0001398529,0.00008044611,0.00001282224],"category_scores_gemma":[0.0007761688,0.00009574477,0.0001463316,0.0002433685,0.0003031865,0.000009557219,0.00005201764,0.0002940797,4.986261e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001913526,"about_ca_system_score_gemma":0.0004000257,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001473101,"about_ca_topic_score_gemma":0.000031,"domain_scores_codex":[0.9976666,0.0002556957,0.001508684,0.0002135379,0.0002080026,0.0001474873],"domain_scores_gemma":[0.9972967,0.0001084107,0.001915678,0.0001444049,0.0003474291,0.000187365],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.09276463,0.07045126,0.4657255,0.00005762384,0.0008109842,0.0001095378,0.001537707,0.001767725,0.2333805,0.00001416172,0.00115273,0.1322277],"study_design_scores_gemma":[0.09346637,0.7624163,0.103554,0.0001420805,0.000216628,0.00002295105,0.004422318,0.000140378,0.03155605,0.000006132755,0.003675335,0.0003814574],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.998991,0.00002737869,0.0002473624,0.0002747601,0.0001355709,0.0001944703,0.00001092103,0.000001918813,0.0001166671],"genre_scores_gemma":[0.9981853,0.00002679249,0.0007909938,0.0007752641,0.0001914437,0.000003604999,0.000008853966,0.00001371248,0.00000397543],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.691965,"threshold_uncertainty_score":0.3904358,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02776253216202049,"score_gpt":0.3761725389283527,"score_spread":0.3484100067663322,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}